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Abstract Neuronal nicotinic acetylcholine receptors (nAChR) are made from different combinations of subunits encoded by a diverse family of 
genes. However, the recently cloned a7 gene codes for subunits that can form homooligomeric nAChR complexes when expressed in Xenopus oocytes. 
Electrophysiological studies reveal that these all-nAChR function as a-bungarotoxin (Bgt)-sensitive, quickly activating/inactivating ion channels with 
a unique pharmacological profile and an unusually high permeability to calcium ions. Although similar observations have been made in studies of 
Bgt-sensitive, functional nAChR subtypes that are naturally expressed in neuronal cells, all attempts until now to reconstitute functional a7-nAChR 
in cell lines have failed. Here we report the successful use of SH-SYSY human neuroblastoma cells, which naturally express low levels of endogenous 
a7 transcripts, to stably overexpress heterologous rat nAChR a7 transgenes. These transgenes are expressed asthe appropriately-sized a7 messages 
and protein, and stably transfected SH-SYSY cells have over 30-times higher levels of specific Bgt binding sites than do wild-type cells. Whole cell 
current recordings confhm that transfected cells express functional nAChR that are sensitive to blockade by Bgt and display the typical physiological 
and pharmacological profiles of a7-nAChR. We conclude that stable, functional expression of a7 transgenes in a mammalian cell line has been 
achieved for the first time. 
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1. lntroauction 
Nicotinic acetylcholine receptors (nAChR) exist as diverse 
members of the ligand-gated ion channel (LGIC) superfamily 
of neurotransmitter eceptors [l-3]. Part of the diversity in 
nAChR is attributable to the existence of at least fifteen differ- 
ent nAChR subunit genes. Proteins encoded by these genes 
combine in different ways to generate several unique nAChR 
subtypes. However, roles of nAChR subunits, particularly in 
the formation and function of neuronal nAChR, are incom- 
pletely understood. 
NeuronaYnicotinic alpha-bungarotoxin binding sites (nBgtS) 
represent a unique class of nAChR that was first discovered in 
autonomic and CNS neurons or nervous tissue based on their 
ability to bind radiolabeled, curaremimetic neurotoxins such as 
a-bungarotoxin (Bgt) with high affiity and specificity [2,4-g]. 
Found where nAChR expression was expected, nBgtS also 
display a clearly nicotinic ligand binding profile, possess many 
of the physical and chemical properties of other nAChR, and 
have drug reactivities consistent with roles as LGIC. However, 
whereas studies of autonomic or CNS neurons that express 
nBgtS detected functional nAChR responses involved in the 
mediation of excitatory neurotransmission, those responses 
were not demonstrated to be sensitive to blockade by curarem- 
imetic neurotoxins (although there were some exceptions; op. 
cit.). Thus, functional relevance of nBgtS and their identity as 
LGIC was questioned. 
Critical breakthroughs in our understanding of nBgtS were 
the cloning of what is now known as the chick nAChR a7 
subunit gene and technical improvements allowing the detec- 
tion of transient and novel functional responses of nAChR 
made up of a7 subunits [10-l 11. The protein products of chick, 
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rat or human a7 genes can form homooligomeric complexes in 
Xenopus oocytes that can bind curaremimetic neurotoxins and 
can mediate very short-lived, nicotine-gated, toxin-sensitive, 
ion channel responses [10,12-141. These homooligomeric, 
transgenic a7 subunit-containing nAChR (a7-nAChR) have 
unique properties including high Ca2’ permeability (op. cit.). 
Based on the breakthrough recognition that toxin-sensitive a7- 
nAChR responses have lifetimes of tens of milliseconds and 
include contributions from inward Ca” currents, searches for 
functions of natural nBgtS were renewed. These studies uncov- 
ered short-lived, nicotine-gated, toxin-sensitive, inward cur- 
rents andlor elevations of intracellular Ca” in chick autonomic 
neurons [ 15-161 and in rat CNS neurons [ 17-201 that also have 
been shown to express natural a7 genes and entities corre- 
sponding to native nBgtS [2,5,21]. Thus, correlations have been 
drawn between the expression of nBgtS, a7 gene products, and 
toxin-sensitive, functional nAChR responses. 
Described here are studies that further examine these rela- 
tionships using a human ganglionic neuronal cell line as a 
model and as a host for expression of a7 subunit transgenes. 
Preliminary accounts of this work have appeared [22-231. 
2. Materials and methods 
2.1. Cell culture 
Wild-type (WI) SH-SYSY cells [24] were maintained in serum 
(Hyclone)-supplemented medium (Gibco BRL) as previously described 
~251. 
2.2. Construction of a7lpCEP4 vector and stable transfection of 
SH-S Y5 Y cells 
An EcoRI fragment of approximately 1.9 kb containing full length 
cDNA sequences of the rat nAChR a7 subunit was excised from its 
original clone [13] (generous gift of Dr. Jim Patrick, Baylor College of 
Medicine) and subcloned as a blunt-ended fragment into the Hind111 
site of the pCEP4 vector (Invitrogen). SH-SYSY cells were transfected 
either with the insertless pCEP4 vector (as a control) or with the a7/ 
pCEP4 vector via a standard electroporation technique (Bio-Rad). 
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Briefly, a 200-V field was applied to a mixture of approximately 10’ cells 
and 20 pg of DNA. Selection of stably transfected cells was carried out 
by culturing as described above but in medium supplemented with 400 
pg/rnl of hygromycin B. 
2.3. Northern blot analysis 
Northern analysis of poly(A)+RNA extracted by the Fast Track 
(Invitrogen) technique was performed as described [25-261 following 
resolution of RNA on a 1% agarose gel using a ‘*P-labeled, full-length, 
rat nAChR u7 subunit cDNA probe [13]. 
2.4. Membrane fraction preparation and I-Bgt binding assays 
Cellular membrane fractions were obtained and ‘251-labeled Bgt 
(I-Bgt; Amersham) binding assays using membrane fractions or intact 
cells in situ were performed as described [26] using native Bgt (purified 
according to [271 from crude venom obtained from Miami Serpentar- 
ium) to standardize specific activity of I-Bgt and to detine non-specific 
binding. 
2.5. Affinity purification of Bgt-binding components 
Briefly (detailed protocol of Drisdel, Puchacz and Lukas to be pub- 
lished elsewhere), cc7-transfected SH-SYSY cells were lysed in Ringer’s 
buffer [271 supplemented with protease inhibitors [28] and 2% Triton 
X-100. Toxin binding proteins were purified using najatoxin (purified 
according to [271 from crude venom obtained from Miami Serpen- 
tarium)-Acti-Gel (Sterogene) affinity chromatography [29], eluted 
using Acti-Sep (Sterogene) solution, and trace-radiolabeled with ‘*‘I 
(Amersham) using iodo-beads (Pierce). Samples were desalted and re- 
solved via electrophoresis on 10% sodium dodecyl sulfate/poly- 
acrylamide gels (SDS-PAGE). Dried gels were exposed at -84°C to 
Kodak XAR film juxtaposed with an intensifying screen for autoradi- 
ography to identify components of toxin-binding material. 
2.6. Electrophysiology 
Whole cell recordings were done using standard techniques initially 
described by [30]. Borosilicate electrodes fashioned on a BB-CH-PC 
pipette puller (Mecanex) and filled with intracellular salt solution (con- 
taming 120 mM KF, 20 mM KCl, 5 mM NaCl, 2 mM MgCl,, 10 mM 
HEPES and 0.5 mM EGTA, pH was adjusted to 7.4 with KOH) were 
used for recording (Axopatch 200A amplifier, Axon Instruments). Data 
was filtered at 2 kHz, acquired at 5 kHz, and analyzed using a personal 
computer equipped with an analog to digital converter (ATMIO-16D, 
National Instrument) and the DATAC package [31]. Drugs were deliv- 
ered in the millisecond range by means of a fast, multibarrel, puffer 
technique (Hu, Maury, Buisson and Bertrand, manuscript in prepara- 
tion). Recordings were usually done one-to-four days after plating of 
cells onto coverslips attached to the bottoms of modified 35 mm Petri 
dishes to also allow high power microscopic examination of cultures. 
Cells were rinsed three times in fresh extracellular salt medium (120 mM 
NaCl, 5 mM KCl, 2 mM MgCl,, 2 mM CaCl,, 25 mM o-glucose, 10 
mM HEPES; pH was adjusted to 7.4 with NaOH) prior to recording 
and were continuously superfused with this medium between drug ap- 
plications. Atropine (1 p-M) was added to bath solutions to prevent 
activation of endogenous muscarinic receptors [32-331. Bgt used in 
electrophysiological studies was purchased from Molecular Probes. 
2.7. Other materials 
Unless otherwise noted above, other reagents were obtained from 
commercial sources such as New England BioLabs, Sigma, Fluka, or 
RBI. 
3. Resultsanddiscussion 
SH-SYSY cells stably transfected with the rat nAChR a7 
subunit-based a7/pCEP4 construct appropriately express the 
transgene as mRNA. Northern analysis (Fig. 1) shows that 
endogenous a7 transcripts are evident (although at low levels; 
see legend) in control SH-SYSY human neuroblastoma cells 
transfected with only the insertless vector (or in WT cells; not 
shown here). However, much higher levels of mRNA hybridiz- 
ing with a7 cDNA probes are expressed in SH-SYSY cells 
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Fig. 1. Northern blot for RNA preparations from control SH-SYSY 
cells transfected with the pCEP4 vector alone (pCEP4; 10 pg 
poly(A)+RNA) or from SH-SYSY cells transfected with the a7/pCEP4 
vector (a7/pCEP4; 8.5 pg poly(A)+RNA) probed with full-length a7 
nAChR cDNA. Autoradiogram was exposed for 4 days at -84°C with 
an intensifying screen to permit visualization of native a7 mRNA from 
control cells. Densitometric analyses of this and other Northern blots 
indicates that a7-transfected cells have at least 6-fold more a7 message 
than do control cells. Approximate position of 18s ribosomal RNA as 
a reference is indicated. 
transfected with full-length rat a7 transgenes (Fig. 1). Moreo- 
ver, these transgene products are processed to the same two, 
predominant sizes as is seen for native human a7 messages in 
control SH-SYSY cells, suggesting that transcription and proc- 
essing to these forms of mRNA are the same from endogenous 
or transgenic templates. Continuing studies will determine 
whether long-term expression of a7 transgenes has any effect 
on expression of native a7 or other nAChR genes in SH-SYSY 
cells. 
SH-SYSY cells stably transfected with a7 cDNA also express 
the appropriate a7 protein product. Toxin binding proteins 
affinity purified from non-ionic detergent-solubilized mem- 
brane extracts of a7-transfected SH-SYSY cells, when resolved 
on SDS-PAGE and visualized by trace radioiodination and 
autoradiography, include a predominant polypeptide of about 
67 kDa (Fig. 2). This polypeptide corresponds to the highest 
molecular mass species from a possibly multi-component, na- 
tive nBgtS identified in WT SH-SYSY cells [34]. The -67 kDa 
polypeptide also comigrates with the peptide from native nBgtS 
that is reactive on Western immunoblots with an antisera raised 
against a unique peptide corresponding to sequences in the 
putative cytoplasmic domain of the a7 protein [34]. Yet to be 
80 kD - 
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Fig. 2. Autoradiogram of trace radioiodinated, najatoxin-Acti-Gel- 
purified components from SH-SYSY cells transfected with rat a7 trans- 
genes. Positions of protein standards of know size are indicated. 
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Fig. 3. Comparison of specific I-Bgt binding levels in membrane prep- 
arations from wild-type (WI), pCEP4-transfected (pCEP4), or a71 
pCEP4-transfected (a7/pCEP4) SH-SYSY cells. Values represent 
means plus/minus standard deviation for the indicated number of rep- 
licate studies (n = 9-12) each done using samples in triplicate. 
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determined in future work is whether exogenous a7 subunits 
are expressed in transfected SH-SYSY cells as homooligomers, 
as chimeric homooligomers containing exogenous rat and na- 
tive human a7 subunits, and/or as chimeric heterooligomers 
containing transgenic rat a7 subunits plus other, presently un- 
identified subunits. 
Our previous studies demonstrated expression of native 
nBgtS in SH-SYSY cells [25l. However, a7-transfected SH- 
SYSY cells have over 30-fold higher levels of specific, I-Bgt 
binding sites than do control WT cells or control cells trans- 
fected with the insertless pCEP4 vector alone (Fig. 3). This 
higher level of expression of I-Bgt binding sites in transfected 
cells is observed in assays using total membrane preparations 
or intact cells in situ, suggesting that exogenous a7 subunits can 
form complexes that are inserted into the plasma membrane. 
a7-transfected cells stably express functional, Bgt-sensitive 
nAChR that quickly activate and inactivate on exposure to 
nicotinic agonists. Passive or voltage-dependent electrical re- 
sponses of WT or transfected SH-SYSY cells are not signiti- 
cantly different (data not shown). Whole cell currents recorded 
in a large sample of either WT or a7-transfected cells (n = 120) 
show peak responses ranging from 50 to 3,000 pA when cells 
are challenged with short pulses of agonist (50 ms of 100 ,uM 
nicotine; sample traces shown in Fig. 4). Data obtained using 
WT cells are comparable to those previously reported for SH- 
SYSY cells in response to longer agonist applications [35]. 
However, analysis of peak current amplitudes and times-to- 
peak reveals important differences between functional nAChR 
responses in WT and transfected cells. Transfected cells mainly 
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Fig. 4. a7-transfected cells display a fast inactivating, nicotine-evoked current. Each cell was held at -100 mV, and amplitude and time-to-peak of 
current evoked by a 50 ms pulse of saturating nicotine (100 PM) was measured. Values of current amplitudes determined in 58 a7-transfected cells 
(dots) and 26 WI cells (triangles) are plotted as a function of their time-to-peak. Typical recordings obtained in response to a pulse of saturating 
nicotine (300 PM) for WI cells and for a7-transfected (a7) cells are shown in the inset. 
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Fig. 5. Physiological characteristics of the fast inactivating, Bgt-sensitive responses of a7-transfected cells. (A) Whole cell recordings ofcurrents evoked 
by ACh at three concentrations are superimposed. Pulse duration (50 ms) is illustrated by the bar. Applications were done once every 3 s beginning 
with the lowest concentration. (B) Dose-response curves for ACh (filled squares, 12 cells) and nicotine (open triangles, 11 cells). Currents evoked 
by short pulses of agonists given from lowest to higher concentrations were measured in cells held at -100 mV (see panel A). Currents were normalized 
to their maximum value and plotted as a function of the logarithm of the agonist concentration. Continuous lines were obtained using the empirical 
Hill equation. The best fit for ACh was obtained with an EC,, of 150,~M and a Hill coefficient of 1.3, whereas for nicotine the values were, respectively, 
25 PM and 1.3. (C) Nicotine-evoked current (100 PM, 50 ms) is blocked by a-Bgt. Nicotine-evoked current recorded as described above prior to 
(control) and after (a-Bgt; 100 nM) 1 min perfusion with a-Bgt as indicated. (D) Nicotine-evoked currents are strongly voltage dependent. Currents 
evoked by short pulses (300 ,uM, 50 ms) were recorded (in 3 cells) at several different holding potentials. Current-voltage relationships were then 
obtained by plotting the peak of the evoked current as a function of the holding potential. Currents were plotted relative to their maximal values 
determined at -108 mV. Error bars, within the symbol size, are omitted 
display fast activating/inactivating currents (7 ms mean time-to- 
peak) whereas slower current responses are observed in WT 
cells (119 ms mean time-to-peak). Nicotine-activated responses 
in cells transfected only with the insertless pCEP4 vector (n = 6; 
data not shown) are indistinguishable from those for WT cells, 
indicating that fast inactivating currents are attributable only 
to expression of rat a7 cDNA and not to simple vector transfec- 
tion. WT SH-SYSY cells naturally express human nBgtS and 
a7 subunits as message and/or protein (Fig. 1) [14,25,34]. How- 
ever, no fast transient was observed in any of the WT cells 
challenged with either acetylcholine (ACh) or nicotine. This 
suggests either that endogenous a7 subunits (and/or nBgtS) are 
expressed only by a small fraction of WT cells or that protein 
levels are so low that the resulting currents are masked by the 
response(s) of another class(es) of endogenous nAChR [25,35]. 
It was previously shown that homooligomeric nAChR com- 
posed of either chicken or rat a7 subunits and expressed in 
Xenopus oocytes are very permeable to calcium ions [8,13,36, 
371 and indirectly mediate activation of a calcium-dependent 
chloride conductance. However, no chloride contribution was 
detected in the ACh-evoked responses recorded in a7-express- 
ing cells. This result probably derives from the calcium buffer- 
ing capacity of the EGTAKF-containing intracellular medium 
and to good exchange between the recording pipette solution 
and the cytosol. Other studies indicate that the physiological 
and pharmacological protiles of the nAChR mediating tran- 
sient currents in a7-transfected cells closely resemble those ob- 
served for native, Bgt-sensitive nAChR and/or for homooli- 
gomeric a7-nAChR expressed in Xenopus oocytes [13,17-191. 
First, for nicotine and acetylcholine (ACh), respective EC,, 
values are 25-27 and 129-150 PM for rat nBgtS or a7-nAChR 
(op. cit.) compared to 25 and 150 PM for peak currents in 
a7-transfected cells (Fig. 5B; sample traces shown in Fig. 5A) 
and in contrast to 20 and 63 PM for the sustained and longer 
time-to-peak currents in WT SH-SYSY cells (data not shown). 
Second, one minute superfusion of a7-transfected cells with 100 
nM Bgt strongly inhibits agonist-evoked currents (n = 3; Fig. 
SC) whereas nicotinic currents of WT cells are unaffected under 
the same conditions (n = 6; data not shown). Similarly, preincu- 
bation of transfected cells with 60 nM Bgt reduces nicotine- 
evoked, fast-transient currents to undetectable levels. More- 
over, methyllycaconitine (MLA), which is a highly-selective 
antagonist of Bgt-sensitive nicotinic responses [38], produces 
92% inhibition (at 1 nM) of the current evoked by 1 mM ACh 
(50 ms) in transfected cells (n = 3). Two surprising observations 
warrant mention. One is that slower, nicotine- or ACh-evoked 
currents resembling those seen in WT cells were still observed 
in some, but not all, of the transfected cells investigated after 
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Bgt or MLA blockade. Another is that nicotine-evoked cur- 
rents measured 120 ms after the onset of agonist application, 
which should be dominated by activation of Bgt-insensitive 
nAChR, were 166 f 32 pA in a7-transfected cells (n = 27) but 
were 358 f 47 pA in WT cells (n = 26). The idea that transgenic 
a7 subunit expression can influence expression of other nAChR 
subunits and functional nAChR subtypes will be explored in 
continuing studies with a7-transfected SH-SYSY cells. Finally, 
the current-voltage relationship for nicotine-evoked responses 
in a7-transfected cells strongly rectifies (Fig. 5D) and compares 
well with that previously described either for homooligomeric 
a7-nAChR heterologously expressed in Xenopus oocytes 
[10,13-141 or for transient functional responses of native, Bgt- 
sensitive nAChR [18-191. 
Collectively, these results show, for the first time and after 
failures to achieve such a result in work in a variety of other 
laboratories, (i) that a mammalian cell line can be stably trans- 
fected to overexpress a7 mRNA and protein from a transgenic 
template and (ii) that transgenic a7 subunits can assemble into 
a nAChR subtype(s) that is capable of binding curaremimetic 
neurotoxins and nicotinic ligands and functioning as a toxin- 
sensitive LGIC with unique physiological and pharmacological 
properties. The results also support a role for a7 subunits in the 
ganglionic nAChR subtype (nBgtS) identified by I-Bgt binding 
[25]. The development of this transfected cell line provides 
opportunities for a number of studies employing multidiscipli- 
nary techniques that could lend further insight into the compo- 
sition, structure and function of the physiologically important 
nAChR family. 
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